A Randomized, Open label, Comparative Clinical Study to Evaluate the Efficacy and Safety of Cystone Forte Tablet in Urolithiasis

The Himalaya Drug Company0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Subject with Urolithiasis as diagnosed by clinical with calculi measuring 5 to 12 mm.
•Hematologic and Biochemical parameters within normal limits (Study specific parameters: calcium, uric acid cannot be more than 2 times upper limit of normal value).Willing to sign inform consent document.

•Subjects with severe obstructive uropathy,those with serious systemic medical disorder- Hypertension, Severe Diabetes, Metabolic disorders, Endocrinal disorders, cardiac illness,the subjects not to have used any drugs, for at least 1 week prior to the study for concurrent illness with diabetes and Hypertension.
•Subjects with a strong history of food or drug allergy of any kind,Subjects not to have been on weight reducing diets within 3 months prior to the start of the study.Pregnant and lactating women
•Patients unwilling to provide informed consent or abide by the requirements of the study.

发起方